<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45227">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01904526</url>
  </required_header>
  <id_info>
    <org_study_id>1110009133</org_study_id>
    <secondary_id>R01DA035001</secondary_id>
    <nct_id>NCT01904526</nct_id>
  </id_info>
  <brief_title>PK/PD Comparison of Guanfacine ER and IR</brief_title>
  <official_title>Pharmacokinetic/Dynamic (PK/PD) Comparison of Guanfacine Extended Release (ER) and Immediate Release (IR) in Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate whether a 4mg/day or 6/mg day dose of extended-release guanfacine produces
      pharmacokinetic/dynamic (PK/PD) properties similar to 3mg/day immediate release guanfacine.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Evaluate whether a 4mg/day or 6mg/day dose of extended-release guanfacine produces PK properties similar to 3mg/day immediate release guanfacine.</measure>
    <time_frame>Lab Sessions (Days 22, 49, 58)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma trough levels of guanfacine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the safety and tolerability of guanfacine</measure>
    <time_frame>Day 1 of titration 1 to the end of followup following the 3rd lab session, which on average will be 2 months.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Heart rate and Blood Pressure throughout the study</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Smoking</condition>
  <arm_group>
    <arm_group_label>Guanfacine 3 mg/day IR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Guanfacine 3 mg/day immediate release</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Guanfacine 4mg/day ER</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Guanfacine 4mg/day extended release</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Guanfacine 6mg/day ER</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Guanfacine 6 mg/day extended release</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Guanfacine</intervention_name>
    <description>3mg/day IR with 3-week lead-in period. Maintained at steady state to complete lab session. After completion of lab session, 1-week lead-in medication period to 4mg/day ER. Maintained at steady state to complete lab session. After completion of lab session, 1-week lead-in medication period to 6mg/day ER. Maintained at steady state to complete lab session. 5-day taper after lab.</description>
    <arm_group_label>Guanfacine 3 mg/day IR</arm_group_label>
    <arm_group_label>Guanfacine 4mg/day ER</arm_group_label>
    <arm_group_label>Guanfacine 6mg/day ER</arm_group_label>
    <other_name>Tenex</other_name>
    <other_name>Intuniv</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-65

          -  Able to read, write and comprehend English

          -  Smoker

          -  Able to take oral medications and willing to adhere to medication regimen

          -  Provide evidence of a stable living residence in the last 2 months, have reasonable
             transportation to the study site, and have no plans to move within the next 3 months
             or unresolved legal problems.

        Exclusion Criteria:

          -  Any significant current medical conditions that would contraindicate smoking

          -  Current Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) abuse or
             dependence of other substances, other than nicotine dependence or alcohol abuse

          -  Positive test results at intake appointment on urine drug screens for illicit drugs

          -  Past 30 day use of psychoactive drugs including anxiolytics and antidepressants

          -  Women who are pregnant or nursing

          -  Suicidal, homicidal or evidence of current mental illness such as schizophrenia,
             bipolar disorder or major depression, or anxiety disorders

          -  Meeting DSM-IV criteria for current attention deficit hyperactivity disorder (ADHD)

          -  Individuals who are currently taking medications known to be effective for smoking
             cessation or are regular users of other tobacco products in the past 30 days

          -  Only one member per household can participate in the study

          -  Specific exclusions for administration of guanfacine not already specified include:

               -  EKG evidence at baseline screening of any clinically significant conduction
                  abnormalities or arrhythmias

               -  Known intolerance for guanfacine or any alpha blocker

               -  History of fainting, syncopal attacks

               -  Heart failure or myocardial infarction

               -  Impaired liver (as indicated by aspartate aminotransferase (AST), alanine
                  aminotransferase (ALT) &gt;3x normal)

               -  Renal function (as indicated by estimated creatinine clearance &lt;60cc/min)

               -  Treatment with any antihypertensive drug or any alpha-adrenergic blocker

               -  Use of any central nervous system depressant (e.g., phenothiazines,
                  barbiturates, benzodiazepines)

               -  Use of strong cytochrome P450 3A4 (CYP3A4) inhibitors (e.g., ketoconazole) or
                  inducers (e.g., rifampin), or consumption of grapefruit juice

          -  Subjects may have not donated blood in the past 8 weeks or have been involved in
             other investigational studies that involve substantial blood draws or medications
             unknown to us
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sherry A McKee, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale Center for Clinical Investigations, Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 8, 2014</lastchanged_date>
  <firstreceived_date>July 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Sherry McKee</investigator_full_name>
    <investigator_title>Associate Professor of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>Guanfacine</keyword>
  <keyword>PK/PD</keyword>
  <keyword>Smokers</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Smoking</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Guanfacine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
